(Q39707313)

English

The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Maria Prins

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Mirjam Kretzschmar

4

object named as

Mirjam Kretzschmar

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

7

object named as

Roel Coutinho

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Amy Matser

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Anouk Urbanus

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Ronald Geskus

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Maria Xiridou

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Marcel Buster

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

614-623

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Hepatitis C: an epidemiological review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modeling the hepatitis C virus epidemic in France

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Comparing the public health burden of chronic hepatitis C and HIV infection in France

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modelling the past, current and future HCV burden in France: detailed analysis and perspectives

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modelling and calibration of the hepatitis C epidemic in Australia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Mathematical modelling of hepatitis C treatment for injecting drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Estimating heroin epidemics with data of patients in methadone maintenance treatment, collected during a single treatment day.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Survival benefit after liver transplantation: a single European center experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

High incidence of hepatitis C virus reinfection within a cohort of injecting drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Protection against persistence of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Hepatitis C virus reinfection in injection drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Central Asia: hotspot in the worldwide HIV epidemic

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

1 reference

https://api.crossref.org/works/10.1111%2FJ.1360-0443.2011.03654.X

21 January 2018

Identifiers

10.1111/J.1360-0443.2011.03654.X

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39707313&oldid=2089055447"